Skip to main content
Premium Trial:

Request an Annual Quote

NuProbe Augury

NuProbe has launched an early-access program for its "Augury" platform, an automated design product for customized liquid biopsy NGS panels. Based on proprietary sequence-design algorithms, Augury procedurally generates NGS panels for cell-free DNA analysis, covering the entire coding regions of between one and 30 genes of interest. 

According to the company, these panels typically detect mutations down to 0.2 percent variant allele frequency, and copy number variations down to 4 percent tumor fraction, using 10 to 20 ng of cell-free DNA input. Users can choose to build panels that either cover the full coding regions of the genes of interest, or select hotspot loci. NuProbe expects typical panels to be designed within two days and analytically validated within 12 weeks.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.